Sign In
Buy VSTM
$3.62
-0.190 (-4.99%)
At Close: Jun 03, 2026
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
07:05am, Tuesday, 18'th Apr 2023
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at
7 Very Undervalued Penny Stocks to Buy in April 2023
05:39pm, Thursday, 06'th Apr 2023
Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.
Top 3 stocks under $1 to buy in March
09:26am, Tuesday, 14'th Mar 2023
With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:33pm, Monday, 30'th Jan 2023
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Verastem: Looking Increasingly Attractive
09:25am, Wednesday, 29'th Jun 2022
Verastem's RAF/MEK/FAK inhibitor program is progressing nicely. They are releasing decent data with no sudden surprises.
3 Top Penny Stocks to Add to Your July 2022 Watchlist
07:58pm, Friday, 24'th Jun 2022
Here's three penny stocks to watch in July 2022 The post 3 Top Penny Stocks to Add to Your July 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
02:35pm, Tuesday, 07'th Jun 2022
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (
Best Penny Stocks to Buy in June 2022? 3 to Watch This Week
10:00am, Sunday, 22'nd May 2022
Check these penny stocks out for your June watchlist The post Best Penny Stocks to Buy in June 2022? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
7 Cheap Biotech Stocks to Buy Now
06:00pm, Thursday, 19'th May 2022
These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on Inves
Verastem: Time To Take My Position Out Of Mothball
09:49am, Tuesday, 19'th Apr 2022
Verastem recently reported their Q4 and full-year 2021 earnings that revealed substantial headway in their pipeline and on the balance sheet. Verastem secured up to $150M in non-dilutive funding from
3 Penny Stocks to Watch With Above Average Volume Today
03:05pm, Monday, 18'th Apr 2022
Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today appeared first on Penny Stocks to Buy, Picks, News and Information | P
Top Penny Stocks Under $2 to Watch As Inflation Rises
08:25pm, Friday, 15'th Apr 2022
Here are three penny stocks under $2 to watch right now The post Top Penny Stocks Under $2 to Watch As Inflation Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.
Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development
01:57pm, Monday, 28'th Mar 2022
Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to $150 million to primarily support the continued development, commercial preparation, and pote
Verastem initiated with a buy at Truist as stock is undervalued; shares up 21%
06:06pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Truist has initiated Verastem (VSTM) with a buy saying that the stock is undervalued given its two clinical cancer candidates, VS-6766 and defactinib.
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why
12:56pm, Wednesday, 09'th Mar 2022
Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trad
